New York City, NY -- (SBWIRE) -- 08/20/2013 -- StockMarketIntel.com issues a special report on the following stocks: Cellceutix Corp (OTCBB:CTIX), Affymax, Inc. (OTCMKTS:AFFY), Blue Earth Inc (OTCMKTS:BBLU), Arch Therapeutics Inc (OTCBB:ARTH)
Cellceutix Corp (OTCBB:CTIX) gained 1.01%, trading on 305,114 shares, to end the trade at $2.00. If we look at its trading history of the past 52 weeks, the share price suffered a low of $.60 and was moved to the maximum level of $2.47. The stock changed hands in a range of $1.96 to $2.05, bringing its market capitalization to about $186.35 million. Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that the Company is on track to commence a clinical study for its anti-psoriasis drug Prurisol™.
Why Should Investors Buy CTIX After The Recent Gain? Just Go Here and Find Out
Affymax, Inc. (OTCMKTS:AFFY) added 1.27%, to complete the trading session at $1.60, with a total volume of 384,166 shares. The stock, on average, trades on a volume of 1.14 million shares. In the past 52 weeks, the share price has not declined below $0.78 and above $27.74. It floated in a range of $1.54 to $1.63 during the last trading session, with a beta value of 1.46. Its market capitalization now moved to about $59.98 million. Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells.
What was the Moving Force behind AFFY on Bullish Run?Read This Research Report
Blue Earth Inc (OTCMKTS:BBLU) added 7.12% and was in a range of $2.90-$3.16 before closing at $3.16. The share price hit its 52-week low of $0.82 and $3.89 was the best price. The stock completed the day with a total volume of 169,842 shares, versus an average volume of 74,873 shares. Blue Earth, Inc. engages in a mergers and acquisition strategy to acquire, license, develop, market, install, and monitor clean-tech related technologies and energy management systems. The targeted technologies include various measures designed for a specific customer or facility in the target market of small commercial businesses and residences to enhance the efficiency of building systems, such as refrigeration, lighting and heating, ventilation, and air conditioning.
For How Long BBLU will fight for Profitability? Read This Trend Analysis report
Arch Therapeutics Inc (OTCBB:ARTH) declined -18.80% yesterday, bringing its market capitalization around $18.04 million. The total number of shares that changed hands during the session was 1.07 million shares, as compared to average trading volume of 2.22 million shares. The share price, after opening at $0.50, made a high of $0.52 and hovered above $0.37 to end the day at $0.410. Arch Therapeutics, Inc. operates as a life science company developing liquid polymers containing tiny peptides intended to form gel-like barriers over surgical wounds to stop or control bleeding. The company was formerly known as Clear Nano Solutions, Inc. It was founded in 2006 and is based in Natick, Massachusetts.
Has ARTH Found The Bottom and Ready To Move Up? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)